tbuckley/cabot-search huggingface dataset:
Abstract 180: Interaction between bone marrow-derived mesenchymal stem cells and tumor cells induces expression of fibronectin in human colon cancer cells
Authors: Kei Shinagawa, Yasuhiko Kitadai, Yuichiro Tanaka, Ryo Yuge, Mieko Onoyama, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama
Journal: Cancer Research (2014)

Abstract Bone marrow-derived mesenchymal stem cells (MSCs) have been reported to contribute to the formation of tumor stroma. We reported recently that in an orthotopic nude mouse model of human colon cancer, MSCs migrated to tumor stroma, where they differentiated into carcinoma-associated fibroblast (CAF)-like cells and promoted tumor growth and metastasis. However, the molecular mechanisms of this phenomenon have not been elucidated. We performed microarray analysis of gene expression in KM12SM cells and found that expression of fibronectin (FN) mRNA was increased markedly by direct co-culture of KM12SM cells with MSCs. FN, a glycoprotein in extracellular matrix and also a maker of epithelial-mesenchymal transition (EMT), has been implicated in the development of several types of human cancer. Many reports indicate that EMT is an important step during the cascade of tumor progression. However, the potential role of FN in carcinogenesis is not fully elucidated. We examined FN expression in surgical specimens of human colon cancer and colon adenoma by immunohistochemistry. A total of 87 tumors were analyzed. Levels of FN expression in tumor cells correlated with disease stage, and FN immunoreactivity was detected in invasive cancers, especially at the invasive edge, but less in mucosal cancers or adenomas. Furthermore, in an orthotopic nude mouse model of colon cancer, mRNA expression levels of FN were shown to be higher in the tumors produced by KM12SM cells mixed with MSCs than in the tumors produced by KM12SM cells alone.These findings suggest that the interaction between cancer cells and MSCs recruited into tumor stroma may play a role in tumor growth and metastasis via induction of FN expression in invasive colon cancer. Citation Format: Kei Shinagawa, Yasuhiko Kitadai, Yuichiro Tanaka, Ryo Yuge, Mieko Onoyama, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama. Interaction between bone marrow-derived mesenchymal stem cells and tumor cells induces expression of fibronectin in human colon cancer cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 180. doi:10.1158/1538-7445.AM2014-180
Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009.
Authors: L. M. Napolitano, P. K. Park, K. C. Sihler, T. Papadimos, C. Chenoweth, S. Cinti, C. Zalewski, R. Sharangpani, P. Somsel, E. Wells, A. M. Fry, A. E. Fiore, J. M. Villanueva, S. Lindstrom, T. M. Uyeki
Journal: MMWR Morbidity and Mortality Weekly Report (2009)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Authors: Animesh Pardanani, Claire Harrison, Jorge E. Cortes, Francisco Cervantes, Ruben A. Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Eric Jourdan, Alessandro M. Vannucchi, Mark W. Drummond, Mindaugas Jurgutis, Kazimierz Kuliczkowski, Emanuil Gheorghita, Francesco Passamonti, Frank Neumann, Abhay Patki, Guozhi Gao, Ayalew Tefferi
Journal: JAMA Oncology (2015)

IMPORTANCE Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials.OBJECTIVE To evaluate the efficacy and safety of fedratinib therapy in patients with primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF.DESIGN, SETTING, AND PARTICIPANTS Double-blind, randomized, placebo-controlled phase 3 study in 94 sites in 24 countries in which 289 adult patients (Ն18 years of age) with intermediate-2 or high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF were randomly assigned between December 2011 and September 2012 to once-daily oral fedratinib, at a dose of 400 mg or 500 mg, or placebo, for at least 6 consecutive 4-week cycles. MAIN OUTCOMES AND MEASURESThe primary end point was spleen response (Ն35% reduction in spleen volume from baseline as determined by magnetic resonance imaging or computed tomography) at week 24 and confirmed 4 weeks later.The main secondary end point was symptom response (Ն50% reduction in total symptom score, assessed using the modified Myelofibrosis Symptom Assessment Form). RESULTSThe primary end point was achieved by 35 of 96 (36% [95% CI, 27%-46%]) and 39 of 97 (40% [95% CI, 30%-50%]) patients in the fedratinib 400-mg and 500-mg groups, vs 1 of 96 (1% [95% CI, 0%-3%]) in the placebo group (P < .001).Symptom response rates at week 24 were 33 of 91 (36% [95% CI, 26%-46%]), 31 of 91 (34% [95% CI, 24%-44%]), and 6 of 85 (7% [95% CI, 2%-13%]) in the fedratinib 400-mg, 500-mg, and placebo groups, respectively (P < .001).Common adverse events with fedratinib treatment were anemia, gastrointestinal symptoms, and increased levels of liver transaminases, serum creatinine, and pancreatic enzymes.Encephalopathy was reported in 4 women who received fedratinib 500 mg/d.A diagnosis of Wernicke encephalopathy was supported by magnetic resonance imaging in 3 cases and suspected clinically in 1 case.CONCLUSIONS AND RELEVANCE Fedratinib therapy significantly reduced splenomegaly and symptom burden in patients with MF.These benefits were accompanied by toxic effects in some patients, the most important being encephalopathy of unknown mechanism.Clinical development of fedratinib was subsequently discontinued.
Pyk2 and Syk participate in functional activation of granulocytic HL-60 cells in a different manner
Authors: Yasuo Miura, Yumi Tohyama, Terutoshi Hishita, Amitabha Lala, Ernesto De Nardin, Yataro Yoshida, Hirohei Yamamura, Takashi Uchiyama, Kaoru Tohyama
Journal: Blood (2000)
Drug Discount Cards
Authors: Brian Vastag
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACUTE HEMOLYTIC ANEMIA WITH TOXIC HEPATITIS CAUSED BY SULFADIAZINE; REPORT OF A CASE
Authors: Douglas Donald, Richard E. Wunsch
Journal: Annals of Internal Medicine (1944)

Case Reports1 October 1944ACUTE HEMOLYTIC ANEMIA WITH TOXIC HEPATITIS CAUSED BY SULFADIAZINE; REPORT OF A CASEDOUGLAS DONALD, M.D., F.A.C.P., RICHARD E. WUNSCH, M.D.DOUGLAS DONALD, M.D., F.A.C.P.Search for more papers by this author, RICHARD E. WUNSCH, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-21-4-709 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAcute hemolytic anemia resulting from the use of sulfonamides has been frequently reported. Long, Haviland, Edwards and Bliss,1 in a large series, noted its occurrence in 1.8 per cent of cases following the administration of sulfanilamide and in 0.6 per cent after sulfapyridine. This toxic effect was not seen with sulfathiazole.Rothstein and Cohn,2 however, have recently reported one case, and Bunim and Israel3 two cases following sulfathiazole.Sulfadiazine has been considered innocuous as far as the hematopoietic system is concerned. Mild anemias may occur, but to date no case of hemolytic anemia following its use has been reported. For...Bibliography1. LONGHAVILANDEDWARDSBLISS PHJWLBEA: Toxic manifestations of sulfanilamide and its derivatives, with reference to their importance in course of therapy, Jr. Am. Med. Assoc., 1940, cxv, 364. CrossrefGoogle Scholar2. ROTHSTEINCOHN IS: Acute hemolytic anemia, auto-agglutination, toxic hepatitis and renal damage following sulfathiazole therapy, case report, Ann. Int. Med., 1942, xvi, 152-161. Google Scholar3. BUNIMISRAEL JJM: Acute hemolytic anemia caused by sulfathiazole, Ann. Int. Med., 1942, xvi, 333-339. Google Scholar4. PRICEFRISCH AEAW: Sputum studies in pneumonia. The selection of therapy, Ann. Int. Med., 1941, xv, 987-993. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Detroit, Michigan*Received for publication June 29, 1942.From the Medical Clinic of Harper Hospital, Detroit, Michigan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrugs, Chemicals and HemolysisHemolytic anemia due to quinidine: Observations on its mechanism 1 October 1944Volume 21, Issue 4Page: 709-711KeywordsAnemiaHemolytic anemiaHepatitis AHospitalsSulfonamide ePublished: 1 December 2008 Issue Published: 1 October 1944 PDF downloadLoading ...
CONSTITUTIONAL HEPATIC DYSFUNCTION—FAMILIAL NONHEMOLYTIC JAUNDICE
Authors: W B BLANTON, F M BLANTON
Journal: Annals of Internal Medicine (1955)

Case Reports1 September 1955CONSTITUTIONAL HEPATIC DYSFUNCTION—FAMILIAL NONHEMOLYTIC JAUNDICEWYNDHAM B. BLANTON, F.A.C.P., FRANK M. BLANTONWYNDHAM B. BLANTON, F.A.C.P.Search for more papers by this author, FRANK M. BLANTONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-3-598 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMost patients with jaundice are considered to have either organic disease of the liver or biliary passages or hemolytic disease. Occasionally one sees a patient who does not fall into either of these two groups.CASE REPORTA 26 year old male student for the ministry was examined in September, 1951, because of persistent jaundice. He had been well until 1943, at which time he developed diarrhea and was found to be jaundiced. He was put to bed for two weeks. During this time his icterus and diarrhea gradually subsided. Since then he has had frequent exacerbations of jaundice, accompanied...Bibliography1. GilbertLereboullet AP: La cholemie simple familiale, Gaz. hebd. de méd. 49: 887, 1902. Google Scholar2. RozendaalComfortSnell HMMWAM: Slight and latent jaundice, J. A. M. A. 104: 374 (Feb. 2) 1935. CrossrefGoogle Scholar3. DameshekSinger WK: Familial non hemolytic jaundice, Arch. Int. Med. 67: 259 (Feb.) 1941. CrossrefGoogle Scholar4. Meulengracht E: A review of chronic intermittent juvenile jaundice, Quart. J. Med. 16: 83 (Apr.) 1947. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Richmond, Virginia*Received for publication August 6, 1954. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUntersuchungen �ber den Blutumsatz bei posthepatitischen und anderen funktionellen Hyperbilirubin�mienTHE RECOGNITION AND DIFFERENTIAL FEATURES OF INDIRECT REACTING HYPERBILIRUBINEMIA*STANLEY REICHMAN, M.D., WILLIAM D. DAVIS JR., M.D., F.A.C.P. 1 September 1955Volume 43, Issue 3Page: 598-601KeywordsAnemiaDiarrheaEmotionsFallsLiver diseases ePublished: 1 December 2008 Issue Published: 1 September 1955 PDF downloadLoading ...
HIV infections and STI co-infections in men who have sex with men in Belgium: sustained increase in HIV diagnoses
Authors: A Sasse, A Defraye
Journal: Eurosurveillance (2009)

Belgium is currently experiencing an upward trend in the number of new HIV diagnoses characterised by a continuous increase in the number of cases among men who have sex with men (MSM). Based on surveillance data, in the past decade the yearly number of newly diagnosed HIV cases in MSM increased more than threefold, from 101 cases diagnosed in 1999 to 332 cases in 2008. During this period, the majority of new HIV infections in MSM were diagnosed among Belgians citizens (72%), followed by other European nationalities (13%). The increase in HIV diagnoses does not reflect an increase in HIV testing since the number of tests performed nationwide remained remarkably stable over time. The steady increase in the number of newly diagnosed HIV cases among MSM, and the high proportion of MSM among HIV-positive patients co-infected with other sexually transmitted infections (STI) (95.6% in 2008) indicate increases in unsafe sex practices in this group. Development of behavioural surveillance and more qualitative research on reasons for unsafe sex are needed in order to develop more effective prevention strategies.
Large Tumor Suppressor 2, a Downstream Target of Mammalian Sterile 20 Like Kinase 1, Is an Endogenous Regulator of Myocyte Size and Apoptosis in the Heart
Authors: Yutaka Matsui
Journal: Circulation (2008)

Abstract 484 Yutaka Matsui, Noritsugu Nakano, Hiromitsu Takagi, Dan Shao, Shumin Gao, Chull Hong, Peiyong Zhai, UMDNJ, New Jersey Medical Sch, Newark, NJ; Norikazu Yabuta, Osaka Univ, Osaka, Japan; Wufan Tao, Univ of Minnesota, Minneapolis, MN; Hiroshi Nojima, Osaka Univ, Osaka, Japan; Junichi Sadoshima, UMDNJ, New Jersey Medical Sch, Newark, NJ Yutaka Matsui, 2008 Finalist and Presenting Author
Abstract MP58: Association Between Plasma Low-Density Lipoprotein Cholesterol Level and Risk of Abdominal Aortic Aneurysm in ARIC: a Mendelian Randomization Study
Authors: Lu-Chen Weng, Pamela L Lutsey, Alvaro Alonso, Weihua Guan, James S Pankow, Aaron R Folsom, Weihong Tang
Journal: Circulation (2014)

Introduction: Abdominal aortic aneurysm (AAA) is one of the leading causes of death in the United States. Observational epidemiological studies demonstrated that circulating level of LDL cholesterol is positively associated with AAA risk. However, a causal link between LDL and risk of AAA is still unclear. Hypothesis: There is a causal relationship between plasma LDL and risk of AAA, which can be demonstrated by a Mendelian randomization (MR) approach. Methods: Using a gene score for LDL as an instrumental variable (IV), we conducted a large MR study to investigate the association between plasma level of LDL and risk of AAA in 8,967 European Americans in the ARIC Study. Twelve SNPs that were reported in a published genome-wide association study for LDL and not associated with other lipids or total cholesterol (TC) were selected. A weighted LDL gene score was created as the sum of the number of risk alleles of the selected SNPs multiplied by the SNP-specific effect size on LDL obtained from the literature and then divided by the total number of SNPs. For participants who took antihyperlipidemic medication, a constant was added to their plasma LDL value to account for the effect of medication. A total of 262 clinical AAA cases were ascertained through hospital discharge diagnoses or death certificates during 23 years of follow-up. The IV-predicted risk for AAA per 1 SD increment of LDL was assessed using an IV probit model adjusted for age, sex, field center, and 10 principal components to account for population stratification. A probit regression model adjusted for known risk factors and other lipids was also performed to confirm the association between LDL and AAA risk at the phenotype level. Results: Using the LDL gene score as an IV for LDL, a positive association was observed between plasma LDL and the predicted risk of AAA. Each 1 SD increase in LDL (instrumented by the LDL gene score) was associated with an average increase of 10% (95% CI=0.1%- 20%) in the risk of AAA. The strength of the LDL gene score as an IV was adequate (F-statistic = 20), and this score was not related to other risk factors for AAA, including other lipids. Similar results were observed after we removed participants who took antihyperlipidemic medications. The positive association based on the LDL gene score was concordant in direction with the association between LDL level and AAA without gene score (average increase in the risk of AAA per 1 SD increment in LDL = 0.6%, 95%CI=0.3 %-1%). We conducted a sensitivity analysis by adding SNPs related to TC. This new score was marginally correlated with triglycerides and reduced the adequacy of MR model to below statistical significance. Conclusion: Our finding supports a causal relationship between plasma level of LDL and AAA risk, with higher LDL level leading to a higher AAA risk.
Experimentally Induced Vitamin Deficiencies in Man
Authors: S. S. B. Gilder
Journal: BMJ (1950)

A search of the published accounts of experiments designed to induce vitamin deficiencies in man reveals a very uneven distribution of work in relation to the individual accessory food factors.Some vitamins have been the subject of repeated investigations, others have been studied by only one or two investigators, and a few have never received any attention.There are a number of reasons for these discrepancies.In the first place, it is clear that experiments on human
Outcomes of Fresh and Cryopreserved Oocyte Donation
Authors: Vitaly A. Kushnir, David H. Barad, David F. Albertini, Sarah K. Darmon, Norbert Gleicher
Journal: JAMA (2015)

This study used data from the 2013 annual report of US in vitro fertilization center outcomes published by the Society for Assisted Reproductive Technology to compare live birth and cycle cancellation rates using either fresh or cryopreserved donor oocytes.
Abstract 2994: Gender-Related Differences in the Central Arterial Pressure Waveform Begin in Childhood and are Independent of Height
Authors: Julian G Ayer, Albert Avolio, Guy Marks, Jason A Harmer, David S Celermajer
Journal: Circulation (2008)

Introduction Women develop age-related LV hypertrophy and symptomatic heart failure to a greater extent than men. Contributing to this may be a higher pulsatile afterload in women, with a higher central arterial systolic augmentation pressure (AP, peak pressure minus pressure at systolic shoulder) and augmentation index (AIx, ratio of AP to pulse pressure). It is unclear if these differences are due to gender per se or shorter female stature. We studied 8-year old children to determine if gender-related differences in carotid pressure augmentation are present in early life and if so, whether they are independent of height (Ht). Methods 406 children (age 8.0 ± 0.1, 49% girls) had anthropometry, brachial systolic and diastolic BP (SBP, DBP), heart rate (HR) and carotid and radial pressure waveforms (by applanation tonometry, calibrated to mean BP and DBP) assessed. Carotid ultrasound evaluated arterial elasticity [Carotid Artery Compliance (CAC), Stiffness Index (SI) and Young’s Elastic Modulus (YEM)]. Results Boys and girls had a similar Ht (129 ± 6 v 128 ± 6 cm), BMI (17.6 ± 3.1 v 17.5 ± 3.0), SBP (100 ± 7 v 101 ± 5 mmHg), DBP (59 ± 6 v 60 ± 5 mmHg) and HR (80 ± 10 v 82 ± 10 bpm). The carotid AP and AIx were significantly higher in girls (−4 ± 3 v −6 ± 4 mmHg and −12 ± 8 v −16 ± 9 respectively, p &lt; 0.001), indicating greater systolic pressure augmentation. Time to onset of the reflected wave ( Tr ) and time to peak of the reflected wave were shorter in girls (154 ± 19 v 163 ± 18 msec, p &lt; 0.001 and 206 ± 23 v 212 ± 22 msec, p = 0.03 respectively), indicating earlier wave reflection. Girls had a higher velocity index (Vr) estimated from Ht ( Vr = Ht /Tr , 8.4 ± 1.0 v 8.0 ± 0.9 m/sec, p = 0.001). Ejection duration, maximum rate of pressure rise and time to systolic peak (indicating effect of ventricular ejection on the carotid waveform) were not significantly different between genders. Boys, however, had stiffer carotid arteries than girls [lower CAC (5.8 ± 1.5 v 6.2 ± 1.8 %/10 mmHg, p = 0.016), higher SI (2.7 ± 0.7 v 2.5 ± 0.7, p = 0.012) and YEM (735 ± 217 v 681 ± 237, p = 0.021)]. Conclusion Even in the first decade of life, girls demonstrate greater central arterial pressure augmentation than boys, with earlier wave reflection. This is independent of height and may contribute to cardiovascular morbidity in females, later in life.
Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-β1 is a cell cycle–independent effect and influences their hematopoietic potential
Authors: Luca Pierelli, Maria Marone, Giuseppina Bonanno, Simona Mozzetti, Sergio Rutella, Roberta Morosetti, Carlo Rumi, Salvatore Mancuso, Giuseppe Leone, Giovanni Scambia
Journal: Blood (2000)
Standardized Allergen Provocation Test
Authors: O. Loẅhagen, N. B. Lindholm
Journal: Allergy (1980)

Standardized bronchial allergen provocation with the same individual allergen dose was performed 3–9 times in 20 symptomless adult asthmatic patients at intervals of 1 week or more during 1/222 months in order to study variations in bronchial response. The immediate type reaction was recorded by monitoring FEV 1 , FVC, PEFR and MEF 50% for 30–40 min after provocation. FEV 1 was highly significantly correlated to the other variables. The coefficient of variation corresponding to maximum decrease in FEV, was 23%. All provocations were followed by a bronchial reaction within clinically acceptable limits. There was no indication of hypo‐ or hypersensitization. It is concluded that although many different factors influence the bronchial response, careful standardization of the provocation procedure leads to a moderate variation in bronchia! response, making the allergen provocation test suitable for pathophysiological studies and clinical evaluation of anti–asthmatic drugs.